Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky et al. · New England Journal of Medicine · 2016 · 2K citations · Full text

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

Allergy, Atopic Dermatitis, Allergy Medicine +8

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

Marjolein de Bruin‐Weller, Diamant Thaçi, Catherine Smith et al. · British Journal of Dermatology · 2017 · 468 citations · Full text

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Sarah Faiz, Jonathan Giovannelli, Céline Podevin et al. · Journal of the American Academy of Dermatology · 2019 · 205 citations

Allergy, Atopic Dermatitis, Allergy Medicine +5

IL-4 abrogates T _H 17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells

Emmanuella Guenova, Yuliya Skabytska, Wolfram Hoetzenecker et al. · Proceedings of the National Academy of Sciences · 2015 · 175 citations · Full text